

### **Corrected Claims:**

In response to the Notice of Non-Compliant Amendment, this listing of claims will replace the prior version submitted with the 14 December 2007 Amendment and Response to Restriction Requirement.

### **Listing of Claims:**

**Claim 1.** (Currently amended) A method for diagnosing a genetic susceptibility for an inflammatory bowel disease in a subject, such method comprising:

- a. obtaining a biological sample containing nucleic acid from said subject, and
- b. analyzing said nucleic acid to detect the presence or absence of a single nucleotide polymorphism in a CSF1R gene ~~selected from the group consisting of FLJ21425 and CSF1R~~, wherein said single nucleotide polymorphism is associated with a genetic predisposition for inflammatory bowel disease.

**Claim 2.** (original) The method of claim 1, wherein at least one single nucleotide polymorphism is located at 2033 base pairs from the 3' end of the eleventh intron of the CSF1R gene.

**Claim 3.** (original) The method of claim 1, wherein said nucleic acid is DNA, RNA, cDNA or mRNA.

**Claim 4.** (original) The method of claim 1, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fraction analysis, oligonucleotide ligation assay or allele specific PCR.

**Claim 5.** (currently amended) The method of claim 4, wherein said analysis is accomplished using primers selected from the group consisting of ~~SEQ. ID. No. 1, SEQ. ID. No. 2, SEQ. ID. No. 3, and SEQ. ID. No. 4.~~

**Claim 6.** (original) A method as in Claim 1, wherein said inflammatory bowel disease is Crohn's disease.

**Claim 7.** (Currently amended) A method of treatment or prophylaxis in a subject, said method comprising:

- a. obtaining a sample of biological material containing nucleic acid from a subject;
- b. analyzing said nucleic acid to detect the presence or absence of a least one single nucleotide polymorphism of a CSF1R gene ~~selected from the group consisting of FLJ21425 and CSF1R~~ associated with a genetic predisposition for inflammatory bowel disease; and
- c. treating the subject for inflammatory bowel disease.

**Claim 8.** (original) The method of claim 7, wherein at least one single nucleotide polymorphism is located at 2033 base pairs from the 3' end of the eleventh intron of the CSF1R gene.

**Claim 9.** (original) The method of claim 7, wherein said nucleic acid is DNA, RNA, cDNA or mRNA.

**Claim 10.** (original) The method of claim 7, wherein said analysis is accomplished by sequencing, mini sequencing, hybridization, restriction fraction analysis, oligonucleotide ligation assay or allele specific PCR.

**Claim 11.** (Currently amended) The method of claim 10, wherein said analysis is accomplished using primers selected from the group consisting of ~~SEQ. ID. No. 1, SEQ. ID. No. 2,~~ SEQ. ID. No. 3, and SEQ. ID. No. 4.

**Claim 12.** (original) A method as in Claim 7, wherein said inflammatory bowel disease is Crohn's disease.

**Claim 13.** (original) A method as in Claim 7, wherein said treatment comprises administering to the subject one or more drugs known to affect expression of the CSF1R gene.

**Claim 14.** (original) A method as in claim 13, wherein said drugs are selected from the group comprising corticosteroids, retinoic acids, interleukin 10, vitamin D3, and mifepristone.